{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:21:46Z","timestamp":1791408106811,"version":"4.3.3"},"reference-count":33,"publisher":"Society of Nuclear Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2026,1]]},"DOI":"10.2967\/jnumed.125.270481","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:00:19Z","timestamp":1764086419000},"page":"96-104","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes of Peptide Receptor Radionuclide Therapy with\n                    <sup>177<\/sup>\n                    Lu-DOTATATE in Patients with Metastatic Pheochromocytoma and Paraganglioma"],"prefix":"10.2967","volume":"67","author":[{"given":"Gokce","family":"Belge Bilgin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Burkett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Bilgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta M.","family":"Durski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann T.","family":"Packard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Navin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorvardur R.","family":"Halfdanarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mabel","family":"Ryder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse Tuba","family":"Kendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"2026010206300906000_67.1.96.1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1498"},{"key":"2026010206300906000_67.1.96.2","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono Study): a European Network for the Study of Adrenal Tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"2026010206300906000_67.1.96.3","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/cancers11071018","article-title":"Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine","volume":"11","author":"Jimenez","year":"2019","journal-title":"Cancers (Basel)."},{"key":"2026010206300906000_67.1.96.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2024.101116"},{"key":"2026010206300906000_67.1.96.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.04.080"},{"key":"2026010206300906000_67.1.96.6","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S2213-8587(23)00256-5","article-title":"Catecholamine-induced hypertensive crises: current insights and management","volume":"11","author":"Nazari","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2026010206300906000_67.1.96.7","doi-asserted-by":"crossref","first-page":"101977","DOI":"10.1016\/j.beem.2025.101977","article-title":"Systemic therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"39","author":"Fischer","year":"2025","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"key":"2026010206300906000_67.1.96.8","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1210\/clinem\/dgaf259","article-title":"Approach to the patient with metastatic pheochromocytoma and paraganglioma","volume":"110","author":"Alkaissi","year":"2025","journal-title":"J Clin Endocrinol Metab."},{"key":"2026010206300906000_67.1.96.9","unstructured":"FDA letter of approval for Lutathera. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2018\/208700Orig1s000ltr.pdf. Accessed November 3, 2025."},{"key":"2026010206300906000_67.1.96.10","unstructured":"FDA approves iobenguane I 131 for rare adrenal gland tumors. Food and Drug Administration website. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-rare-adrenal-tumors. Accessed November 3, 2025."},{"key":"2026010206300906000_67.1.96.11","unstructured":"FDA drug shortages: iobenguane I-131 injection, solution (Azedra injection). Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/scripts\/drugshortages\/dsp_ActiveIngredientDetails.cfm?AI=Iobenguane+I-131+Injection%2C+Solution&st=d&tab=tabs-4&panels=0#xd_co_f=ZjhjZDMzZjgtYmRmOS00NWM4LWEyYjgtYWQ2Y2U4MGY3NGI0\u223c. Accessed November 3, 2025."},{"key":"2026010206300906000_67.1.96.12","unstructured":"FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years and older with GEP-NETS. Food and Drug Administration website. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lutetium-lu-177-dotatate-pediatric-patients-12-years-and-older-gep-nets. Accessed November 3, 2025."},{"key":"2026010206300906000_67.1.96.13","unstructured":"A multicenter open-label study to evaluate safety and dosimetry of Lutathera in adolescent patients with somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas. CCMO website. https:\/\/onderzoekmetmensen.nl\/en\/node\/50857\/pdf. Published June 14, 2021. Updated September 1, 2025. Accessed November 3, 2025."},{"key":"2026010206300906000_67.1.96.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081"},{"key":"2026010206300906000_67.1.96.15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1148\/radiol.2020201745","article-title":"How we do it: a multidisciplinary approach to 177Lu DOTATATE peptide receptor radionuclide therapy","volume":"298","author":"Burkett","year":"2021","journal-title":"Radiology."},{"key":"2026010206300906000_67.1.96.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.230607"},{"key":"2026010206300906000_67.1.96.17","first-page":"334","article-title":"Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma","volume":"52","author":"Forrer","year":"2008","journal-title":"Q J Nucl Med Mol Imaging."},{"key":"2026010206300906000_67.1.96.18","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1530\/EC-20-0292","article-title":"177Lu-DOTATATE therapy in metastatic\/inoperable pheochromocytoma-paraganglioma","volume":"9","author":"Jaiswal","year":"2020","journal-title":"Endocr Connect."},{"key":"2026010206300906000_67.1.96.19","first-page":"1599","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"J Nucl Med."},{"key":"2026010206300906000_67.1.96.20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/EJE-18-0901","article-title":"Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"181","author":"Zandee","year":"2019","journal-title":"Eur J Endocrinol."},{"key":"2026010206300906000_67.1.96.21","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s12020-024-03707-5","article-title":"Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis","volume":"84","author":"Rubino","year":"2024","journal-title":"Endocrine."},{"key":"2026010206300906000_67.1.96.22","doi-asserted-by":"crossref","first-page":"1141648","DOI":"10.3389\/fonc.2023.1141648","article-title":"Peptide receptor radionuclide therapy in advanced pheochromocytomas and paragangliomas: a systematic review and meta-analysis","volume":"13","author":"Su","year":"2023","journal-title":"Front Oncol."},{"key":"2026010206300906000_67.1.96.23","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/RLU.0000000000001629","article-title":"Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with somatostatin receptor expressing neuroendocrine tumors: six years\u2019 assessment","volume":"42","author":"Hamiditabar","year":"2017","journal-title":"Clin Nucl Med."},{"key":"2026010206300906000_67.1.96.24","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/jcm8070952","article-title":"A clinical efficacy of PRRT in patients with advanced, nonresectable, paraganglioma-pheochromocytoma, related to SDHx gene mutation","volume":"8","author":"Kolasinska-\u0106wik\u0142a","year":"2019","journal-title":"J Clin Med."},{"key":"2026010206300906000_67.1.96.25","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"key":"2026010206300906000_67.1.96.26","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1002\/cncr.34191","article-title":"Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu-octreotate peptide radionuclide therapy","volume":"128","author":"Kennedy","year":"2022","journal-title":"Cancer."},{"key":"2026010206300906000_67.1.96.27","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1001\/jamaoncol.2020.0078","article-title":"Assessment of therapy-related myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review","volume":"6","author":"Sonbol","year":"2020","journal-title":"JAMA. Oncol."},{"key":"2026010206300906000_67.1.96.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-007-0691-z"},{"key":"2026010206300906000_67.1.96.29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s13139-015-0332-6","article-title":"The challenges of treating paraganglioma patients with 177Lu-DOTATATE PRRT: catecholamine crises, tumor lysis syndrome and the need for modification of treatment protocols","volume":"49","author":"Makis","year":"2015","journal-title":"Nucl Med Mol Imaging."},{"key":"2026010206300906000_67.1.96.30","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.3390\/curroncol28040247","article-title":"Supportive management of patients with advanced pheochromocytomas and paragangliomas receiving PRRT","volume":"28","author":"Tsang","year":"2021","journal-title":"Curr Oncol."},{"key":"2026010206300906000_67.1.96.31","doi-asserted-by":"crossref","first-page":"1275813","DOI":"10.3389\/fendo.2023.1275813","article-title":"Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [177Lu]Lu-DOTA-TATE therapy","volume":"14","author":"Gubbi","year":"2023","journal-title":"Front Endocrinol (Lausanne)."},{"key":"2026010206300906000_67.1.96.32","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1151-8"},{"key":"2026010206300906000_67.1.96.33","doi-asserted-by":"crossref","first-page":"587065","DOI":"10.3389\/fendo.2020.587065","article-title":"Case report: primary hypothyroidism associated with lutetium 177-DOTATATE therapy for metastatic paraganglioma","volume":"11","author":"Gubbi","year":"2020","journal-title":"Front Endocrinol (Lausanne)."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T14:30:40Z","timestamp":1767364240000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,2]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.2967\/jnumed.125.270481"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270481","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]}}}